-----BEGIN PRIVACY-ENHANCED MESSAGE-----
Proc-Type: 2001,MIC-CLEAR
Originator-Name: webmaster@www.sec.gov
Originator-Key-Asymmetric:
 MFgwCgYEVQgBAQICAf8DSgAwRwJAW2sNKK9AVtBzYZmr6aGjlWyK3XmZv3dTINen
 TWSM7vrzLADbmYQaionwg5sDW3P6oaM5D3tdezXMm7z1T+B+twIDAQAB
MIC-Info: RSA-MD5,RSA,
 DaT77kRGU9LKGBtnok11ayL5kJCJjtJyUCP1s+iPg9wK02bqBFfwRDBqp2wfBcJL
 OFBQBjBFWLStI1hyAFataQ==

<SEC-DOCUMENT>0001144204-07-051049.txt : 20070925
<SEC-HEADER>0001144204-07-051049.hdr.sgml : 20070925
<ACCEPTANCE-DATETIME>20070925164101
ACCESSION NUMBER:		0001144204-07-051049
CONFORMED SUBMISSION TYPE:	6-K
PUBLIC DOCUMENT COUNT:		2
CONFORMED PERIOD OF REPORT:	20070925
FILED AS OF DATE:		20070925
DATE AS OF CHANGE:		20070925

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			XTL BIOPHARMACEUTICALS LTD
		CENTRAL INDEX KEY:			0001023549
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		IRS NUMBER:				000000000

	FILING VALUES:
		FORM TYPE:		6-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	000-51310
		FILM NUMBER:		071134359

	BUSINESS ADDRESS:	
		STREET 1:		711 EXECUTIVE BOULEVARD
		STREET 2:		SUITE Q
		CITY:			VALLEY COTTAGE
		STATE:			NY
		ZIP:			10989
		BUSINESS PHONE:		972-8-930-4440

	MAIL ADDRESS:	
		STREET 1:		711 EXECUTIVE BOULEVARD
		STREET 2:		SUITE Q
		CITY:			VALLEY COTTAGE
		STATE:			NY
		ZIP:			10989
</SEC-HEADER>
<DOCUMENT>
<TYPE>6-K
<SEQUENCE>1
<FILENAME>v088521_6k.htm
<TEXT>
<html>
  <head>
    <title>
</title>
</head>
  <body bgcolor="#ffffff">
    <div>
      <hr style="MARGIN-TOP: -5px; COLOR: #000000" noshade size="4">
      <hr style="MARGIN-TOP: -10px; COLOR: #000000" noshade size="1">
    </div>
    <div style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center">&#160;</div>
    <div style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><strong>UNITED
      STATES</strong></font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><strong>SECURITIES
      AND EXCHANGE COMMISSION</strong></font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><strong>Washington,
      D.C. 20549</strong></font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="center"><br></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><strong>Form
      6-K</strong></font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="center"><br></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><strong>Report
      of Foreign Private Issuer</strong></font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="center"><br></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><strong>Pursuant
      to Rule 13a-16 or 15d-16 </strong></font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><strong>of
      the Securities Exchange Act of 1934</strong></font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="center"><br></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">For
      September 25, 2007</font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="center"><br></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Commission
      File Number: </font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><strong>000-51310</strong></font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="center"><br></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><strong><u>XTL
      Biopharmaceuticals Ltd.</u></strong></font><font id="TAB2" style="COLOR: black; LETTER-SPACING: 27pt">&#160;</font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">(Translation
      of registrant's name into English)</font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="center"><br></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><strong>711
      Executive Blvd., Suite Q</strong></font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><strong><u>Valley
      Cottage, New York 10989</u></strong></font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">(Address
      of principal executive offices)</font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="center"><br></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Indicate
      by check mark whether the registrant files or will file annual reports under
      cover Form 20-F or Form 40-F.</font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify"><br></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Form
      20-F</font><font id="TAB2" style="COLOR: black; LETTER-SPACING: 27pt">&#160;</font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><font style="DISPLAY: inline; FONT-FAMILY: Wingdings">x</font></font><font id="TAB2" style="COLOR: black; LETTER-SPACING: 27pt">&#160;</font><font id="TAB2" style="COLOR: black; LETTER-SPACING: 27pt">&#160;</font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Form
      40-F
<font style="DISPLAY: inline; FONT-FAMILY: Wingdings">o</font></font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="center"><br></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Indicate
      by check mark if the registrant is submitting the Form 6-K in paper as permitted
      by Regulation S-T Rule 101(b)(1): <font style="FONT-FAMILY: Wingdings">o</font></font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify"><br></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Indicate
      by check mark if the registrant is submitting the Form 6-K in paper as permitted
      by Regulation S-T Rule 101(b)(7): <font style="FONT-FAMILY: Wingdings">o</font></font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify"><br></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Indicate
      by check mark whether by furnishing the information contained in this Form,
      the
      registrant is also thereby furnishing the information to the Commission pursuant
      to Rule 12g3-2(b) under the Securities Exchange Act of 1934.</font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify"><br></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Yes
<font style="FONT-FAMILY: Wingdings">o</font></font><font id="TAB2" style="COLOR: black; LETTER-SPACING: 27pt">&#160;</font><font id="TAB2" style="COLOR: black; LETTER-SPACING: 27pt">&#160;</font><font id="TAB2" style="COLOR: black; LETTER-SPACING: 27pt">&#160;</font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">No</font><font id="TAB2" style="COLOR: black; LETTER-SPACING: 27pt">&#160;</font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><font style="DISPLAY: inline; FONT-FAMILY: Wingdings">x</font></font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="center"><br></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">If
&#8220;Yes&#8221;
      is marked, indicate below the file number assigned to the registrant in
      connection with Rule 12g3-2(b): 82-</font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><u>
      N/A
</u></font><font id="TAB2" style="COLOR: black; LETTER-SPACING: 27pt">&#160;</font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><br></div>
    <div>
      <hr style="MARGIN-TOP: -5px; COLOR: #000000" noshade size="1">
      <hr style="MARGIN-TOP: -13px; COLOR: #000000" noshade size="4">
    </div>
    <div>&#160;</div>
    <div id="PGBRK" style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt">
      <div id="FTR">
        <div id="GLFTR" style="WIDTH: 100%" align="left">
        </div>
      </div>
      <div id="PN" style="PAGE-BREAK-AFTER: always">
        <div style="WIDTH: 100%; TEXT-ALIGN: center">
        </div>
        <div style="WIDTH: 100%; TEXT-ALIGN: center">
          <hr style="COLOR: black" noshade size="2">
        </div>
      </div>
      <div id="HDR">
        <div id="GLHDR" style="WIDTH: 100%" align="right">
        </div>
      </div>
    </div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left">&#160;</div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="center"><img src="logo.jpg" alt="XTL Biopharmaceuticals Logo"></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="center"><br>
      <div><br>
        <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 14pt; COLOR: #000000; FONT-FAMILY: Times New Roman"><strong>XTL
          BIOPHARMACEUTICALS LTD. AGM / EGM POSTPONED UNTIL OCTOBER 2,
          2007</strong></font></div>
        <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><br></div>
        <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><strong>Valley
          Cottage, New York, September 25, 2007 </strong></font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">-
          XTL
          Biopharmaceuticals Ltd. (NASDAQ: XTLB; LSE: XTL; TASE: XTL) announces today
          that
          its Annual General Meeting (&#8220;AGM&#8221;) and Extraordinary General Meeting (&#8220;EGM&#8221;) was
          postponed for one week in accordance with its articles of association due
          to the
          absence of a quorum. The postponed AGM and EGM will take place at the Company,
          Building 3, Kiryat Weizmann Science Park, Rehovot, Israel 76100 at 4:00
          pm and
          4:30pm, respectively on October 2, 2007. </font></div>
        <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left">&#160;</div>
        <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Any
          proxy
          votes received at any time up to 48 hours prior to the postponed AGM and
          EGM
          will be included in the total votes counted for the AGM and EGM. Those
          shareholders who have a valid &#8220;proof of ownership&#8221; in Israel or a letter of
          representation from Computershare, the Company&#8217;s registrars, and attend the
          meeting in person will also be permitted to vote.</font></div>
        <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><br></div>
        <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">As
          a
          result of postponing the EGM, the Company anticipates that the time and
          date for
          the cancellation of the listing of its Ordinary Shares from the Official
          List of
          the United Kingdom Listing Authority, being not less than 20 business days
          from
          the date of the EGM as required by the United Kingdom Listing Rules, is
          now 8:00
          am (London Time) on October 31, 2007.</font></div>
        <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><br></div>
        <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><strong>ABOUT
          XTL BIOPHARMACEUTICALS LTD.</strong></font></div>
        <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><br></div>
        <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">XTL
          Biopharmaceuticals Ltd. (&#8220;XTL&#8221;) is engaged in the development of therapeutics
          for the treatment of neuropathic pain and hepatitis C. XTL is developing
          Bicifadine, a serotonin and norepinephrine reuptake inhibitor, for the
          treatment
          of diabetic neuropathic pain. XTL is also developing several novel pre-clinical
          hepatitis C small molecule inhibitors. XTL also has an active in-licensing
          and
          acquisition program designed to identify and acquire additional drug candidates.
          XTL is publicly traded on the NASDAQ, London, and Tel-Aviv Stock Exchanges
          (NASDAQ: XTLB; LSE: XTL; TASE: XTL).</font></div>
        <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><br></div>
        <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Contact:</font></div>
        <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Ron
          Bentsur, Chief Executive Officer</font></div>
        <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Tel:
          +1-(845)-267-0707 ext. 225</font></div>
        <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left">&#160;</div>
        <div id="PGBRK" style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt">
          <div id="FTR">
            <div id="GLFTR" style="WIDTH: 100%" align="left">
            </div>
          </div>
          <div id="PN" style="PAGE-BREAK-AFTER: always">
            <div style="WIDTH: 100%; TEXT-ALIGN: center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">2</font></div>
            <div style="WIDTH: 100%; TEXT-ALIGN: center">
              <hr style="COLOR: black" noshade size="2">
            </div>
          </div>
          <div id="HDR">
            <div id="GLHDR" style="WIDTH: 100%" align="right">
            </div>
          </div>
        </div>
        <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left">&#160;</div>
        <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><br>
          <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><strong>SIGNATURES</strong></font></div>
          <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><br></div>
          <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 36pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Pursuant
            to the requirements of the Securities Exchange Act of 1934, as amended,
            the
            registrant has duly caused this report to be signed on its behalf by
            the
            undersigned, thereunto duly authorized.</font></div>
          <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 36pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left">&#160;</div>
          <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 36pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left">&#160;</div>
          <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left">
            <table align="center" bgcolor="#ffffff" border="0" cellpadding="0" cellspacing="0" width="100%">

                <tr valign="top" bgcolor="#ffffff">
                  <td width="50%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: ">&#160;</font></td>
                  <td width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: ">&#160;</font></td>
                  <td width="49%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: ">&#160;</font></td>
                </tr>
                <tr valign="top" bgcolor="#ffffff">
                  <td><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: ">&#160;</font></td>
                  <td colspan="2">
                    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><strong>XTL
                      BIOPHARMACEUTICALS LTD.</strong></font></div>
                  </td>
                </tr>
                <tr valign="top" bgcolor="#ffffff">
                  <td><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: ">&#160;<br>&#160;</font></td>
                  <td><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: ">&#160;<br>&#160;</font></td>
                  <td><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: ">&#160;<br>&#160;</font></td>
                </tr>
                <tr valign="top" bgcolor="#ffffff">
                  <td>
                    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Date:
                      September 25, 2007</font></div>
                  </td>
                  <td><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: ">By:&#160;&#160;</font></td>
                  <td><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: ">/s/
                    <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Ron
                    Bentsur</font></font></td>
                </tr>
                <tr valign="top" bgcolor="#ffffff">
                  <td colspan="2"><font style="FONT-FAMILY: " size="1">&#160;</font></td>
                  <td align="left">
                    <hr style="COLOR: black" align="left" noshade size="2" width="80%">
                    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Ron
                      Bentsur</font></div>
                  </td>
                </tr>
                <tr valign="top" bgcolor="#ffffff">
                  <td colspan="2"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: ">&#160;</font></td>
                  <td>
                    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Cheif
                      Executive Officer</font></div>
                  </td>
                </tr>

            </table>
          </div>
        </div>
        <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left">&#160;</div>
        <div id="PGBRK" style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt">
          <div id="FTR">
            <div id="GLFTR" style="WIDTH: 100%" align="left">
            </div>
          </div>
          <div id="PN">
            <div style="WIDTH: 100%; TEXT-ALIGN: center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">3</font></div>
            <div style="WIDTH: 100%; TEXT-ALIGN: center">
              <hr style="COLOR: black" noshade size="2">
            </div>
          </div>
          <div id="HDR">
            <div id="GLHDR" style="WIDTH: 100%" align="right">
            </div>
          </div>
        </div>
      </div>
    </div>
  </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>2
<FILENAME>logo.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 logo.jpg
M_]C_X``02D9)1@`!`@``9`!D``#_[``11'5C:WD``0`$````9```_^X`#D%D
M;V)E`&3``````?_;`(0``0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!
M`0$!`0$!`0$!`0$!`0("`@("`@("`@("`P,#`P,#`P,#`P$!`0$!`0$"`0$"
M`@(!`@(#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#
M`P,#`P,#`P,#_\``$0@`/0"D`P$1``(1`0,1`?_$`,T````%!0$!````````
M```````("0H+`0(#!@<%!`$``0,%`0``````````````"``"!P$$!08)`Q``
M``4#`@,$!@0)"`L``````0(#!`41!@<`""$2"3%!$Q1182(5%@IQ,A@Y@9&A
MP6(SLW9WT2,DM+76EUCPL?%"4F,U1387&1$``0($!`(%!P8*"`8#`````0(#
M`!$$!2$2!@<Q05%A<1,(@9&Q(C(4%:'!<B,6-M%"4I*RTG-4=!?A\6(S@Y,D
M&/""PD-3-"4F"?_:``P#`0`"$0,1`#\`?X%/S4]H1Y@J%![::\0D#VG)B*!:
MC^)*-+R1?D#BZP+XR5="JJ-NV#:-PWC.*I%%18(JVXEW,/RH$[3N#-F9@('>
M:@:]J2FJ+A5MV^D("G5!()XS)EYH\:NK;I*1=142[M`)('4(9(3GS8N61S46
M9MO;U;1]O:,D9((!V^`<@RD"1X*2<PE<7B%9,EG,?1<&YFAC$,/()A'CHG:/
MP[BILB<]=_\`+A&8S'J2E/#^O'C$'O;P%-Q4RA$J1)E(@S"I\.'DX<>?.'F^
MW7.-I[D,'XYSE97F4[9R5;$==$:S=T\ZP3D42+&CG8@!0%RS,;D/P"HAV:&J
M\6RIM5VJ+8^Y,L**20,,/FB9K37MWBWLUJ?52\F<OFCM0FY:`(#6O"H@%.SB
M'JU8I<4@95%(5YHR)!7)67A%P5[N;\6JI"/^Z$YNJ$3FQ(/GBOM?I?BT[ZCH
M$4E]+SP/:_2_%I?4=`A2^EYX'M?I?BTOJ.@0I?2\\6^(`&Y1K6E>(<*"-/R:
M;G:"LJ03V0BE/%2I#H,92B`CP`.SM#7MQ$-'=YO5XQDU2'Q\5033`!JH%>P`
M[`[N'=KP+BF7"MXDSPP&$,S.M"7K..<^F/H1$!*(@(CQ_P!X:B'`.'=33V^$
M\V8$\82)2PG/G/C.+CE`P4'TUTG4YDRZX<4@\8^8Q^4]"B!0`*B'I^GUCJCB
MW%HDV,>F**0ZI0=4L!L0`,54"\IA`*B%!#VN'\O=J@J&F7,BU36J/0H2,%IS
M'ICZ$Z`6@5X#3C_L#5PKC.&R`P``'5&3384#2A0-*%"+?6T/O6LO:NKF[9-E
M>X[`NK#CU>?OZW8!LP<FNRQG":1)5T!7C!^8'-N(H&7(4H!XG.(!V:WS;=K3
M=3J%%!J=`50OX((D,JN6:?*-.UP;RQ:U5EG<4EU/$=7DAG=MPZY6[F8RE&65
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M5PWNHHYCWIB-95Z@"C4H"'*0XUJ(ZR&G]J[9>:5>H=8MRN%Q45@#`-@XX@QC
M-0ZUKK+5MV>R.`4=,`$RG,GK,Y&%H-K.9NIC$=*+=#OXW'[EKS5N&XL8R4SM
MWMN290K5Q:L7&D6,CD%TM[H01,>X05`&R(@(I^7$3A[0!J(M26?1CVX5%I'3
MS:/=RL!YPF:<.($N'7/IB0;77:A:T=57:XK6JXH$VP,!VGCAR$CRX#A#:Y#K
MT]4`$4Q-O%NT]4TQ$WAVG41$@"(_]%[Q'1`HV?VY`!4EI24@3Q&)EC+&(G.N
MM<S(2XXF1(D4GICT$>NSU3G!!60W<WFLC7EYTFMKJ%`WH$Q(,Q:_AUZ?RBVY
M?3.EI<PG*<P8M7-R-8,J[IU]0>E.13+#RQC4Z\'5%0/X:^\"[D3T`>15"UDS
M4$*E$2G@Z\=>:MH=NVE=V\TVAP])'X8]&MQM9K3G2MU:.I/X)Q:3KQ=4510$
MD]X5V**CP*FFE:AS&'T`4L)S"/T:>QL[MRM:62EE3B^&4_TF'.;AZU">\"W4
MM])3_5!\^F9U>NHGG/?7M[Q9E#<K=UU6'=UT&87';[MK`IMI-KRI#X*QFT.@
ML4H#7ZIP'B.M5W#VMT?8-*UMRMK.6K8;FD\ISC.:4UEJ"[7QBFKWBIMQ821U
M$$],N42')/KCQX!4`#NH`^C0:GB%<\8)0`!&`'&,VG12&V5\;P=R$7U5(C!3
M#*<XVQ4\S?;MJ*V@1./\B,$_7`CEB"AF8N>0Y1_XZ^O1QVC:+1-5X='M=/TY
M5J!-K>?"\)9T":?)TQS:ON]6X%/XLV=OZ2L6G32[LU3J;_L+("NJ?1A#D5,]
M!.6GL@8P`/=P&E-`OD#)F"`@B<NN.DBE26$2/`&?;%5#CP"H!7@'>-=5&9P^
MJ1DYQ216O)/""P;R)O(MM[;<M3F)QF`R-'6FX7M(;>9GD)?WL5TT*EY)DF@Y
M477%(3T`$S<.[6X;?4]IK=84%'?%)1IUQ\!Y1(!"<<9G#SQ'>[3FH:;;JZ5N
MEPI6H&6"JG2)XJF)3EB?)!/NE=D/=#D#'^07>YM:^%IYE<1$[?\`C>"6@7A(
MPYE:@V06CHXRR0@0*&H;AV]NI)W^LNWECOE$SH);3]&XP%+*%)5)7/%),HB7
MPOW?<RZ6"M7N;WPJVGLK?>`@Y<>D=/#JA5],_LCPI3T]M:?GU!"BXI.9(D>B
M">FC$H([OIZXJ90_"E*"'>`U'UZ1"^[GP7#P`49DD$Q=S#2O,4/IU5M*P).2
M)ZHJ)$8#&,O=_I358;'ERL0PFH]]$RC)K(QDFT<,)&/>(D7:O63I,4G#9PBJ
M4Z:J2J9A`Q3`("`TTU!<:=#S9DY,8]$NB*.H;?94RZ)H4)1&3]<+IHR6P;<Y
M*2]M,SN=OV<I29N3';DB"HH6^]="H\FK->N!(5$7C=4RRR=/9\`Y0"G9H\-I
M=>'4^GFZ-R2KK2^HM)QFW+`CG`L:_P!,U&G[B:AC_P!1U69)'$$&?G'5!A\=
M]<^_K(Z2ER;-Q?2RVX1"4'&-FWT9VL99#"\M'*/7<NLL8XG3=P@@$*BD4:"V
M/S4X!36;CM'3O;@B^-%L6M0[THECW@/"7"1XGKB]9W">:TJ+8@K][0<@,Q[$
MN$SC/HY03;HZ=/"3Z@&[2U;7G6+PV$,;/V=XYBFDB./+O8J-.1RTM(DCRF*C
M+3:HD$HB(\R:9ZZW#=;6C6B-**6C*[=*A.5"`<4`B4P.H8X1B]`::^T]V]YJ
MI^[H,U3XF71V\,>7*)/0V-[(/9C?':]IVX^L-M$-8$EG2$+&O+;-#M&Y&R,<
MI#.&JD:HT\(E!3,F)/5QT!OO-0ESWEE135@S"YD*F>./&"I##*6/=<H+)$I=
M4<K':-M5)RTVR[?@H`%*!<.X\Y0``X!_XX`T#T:O1J#4"02JLJ,>AQ?ZT8I=
MAL^8*-,T0#^2/P1'S_,<V596/^HC(VW85HVO8\$ECNW'`0EGV[#VS$>.Y:,5
M3K^[H5FR:"L83#4_)S#7MT96P=2]4Z:-77NN._6J3)1*C@>DDF!YW6IZ6EOW
M=4S24#NTGU0!B9GEPA>CY9;!>%,E;";DFLBX=Q9?LVCE^[&B4Q>>/[3N:5(T
M([6\)L62FHE\]\!(H`!"<_*4.``&H@WUNETHM8"GHWW6V^ZF`E:DC$\Y$8QO
M^V-JMU;IU3E2TA:BN6(!Y0>OK.;;-O=H]-G<Q/VE@G#5J3\=9IEXZ=MS&%DP
MTPR6*8P<[24CH-L^:*<?KIG*8/3K4ML[Q='M=6YE^I?4@O`*!6HB1ZB2(V+6
MUHMM-I1\LLMI6A,YA(GAT&&-71N$P]2?:B)AYA^+25&A0[$$0[NWZ1XZ+7=9
MH-:%N@!F"B8^2($T(0=3TTN`?'H7$K$'ZT?PZY[\QY?28+X>QY8S:=#(:`YI
MN")M;K)(W///THF`MO/EN3,S).#)D09Q[%45':ZISC0"$)V]^NF>E6JFN\)#
MM/2-..5#EM=IT)`F5+<P!`Y@<^<<?=;5E!9_&C\5KG$M4=-=VWW%*,@E*/65
M,])'#E!Y\H]<-PK<,I$[=<`3F1(F*D7C!U<5P-YXT>_!LX4;@[CBVDA('2;K
M*$'E\;E-3CJ#;)X4%NVQBMU7>Z*WUSS:5!I13-(/`*S2.;IPE!':B\:;K5T?
MH]%:=K;K;FG"GO@%$$CFG)^+T8SCH&WKK98RR!<\+9&;+`E<33\M)MXD9I%4
MZ]JLI!RH5LW0?)R8ISK,5%S%*!CH@4*\:<1UCM;>$K5-@T^[JBPU]-<K8P)J
M;;Q<(Z4Y9@X8QE-`^-+3.I-0-:6U1;GK3<'B`%K5)"23*2LV/5"L6<LPQN&,
M-WUF=:/<7!$V1;JER&91:Z/C2S5)5NDF1DX%0&XD6*X`P&YJ"`:&32%@J-6Z
MDHM*MS8K*NL+*2H2"3CBH<9805FM]9T^B]'7'6"&_>F*2C[\!)!"TX<#Y8X1
MLAWJ0F]2RKDOB`LV9LUM;DZX@58^:<MG2[E4@@`.4S-E5DR)"7C2M=;[N[M-
M4;2Z@I;/7U(J:AZF#@4D$``\C/&<:1LCO)1[RZ;J+U34JJ8-/Y"DD*/3,2)P
MEYHT?>%U*,'[0GJ=M3A)*^\@.$5%O@^U7#(7444$^9NM-+N7"*#5)53V>3F%
M7]$*@.LAM9L3K3=3O;A;O]+9*=/K.NS"29F>0RQ,L>B,!O#XCM$;0)%!6GW[
M43JB$T[,LR<!(KZ!/#IA,T_6YS\*WOLNTHGP&8?'3ECI7X+LK/FYO$.L1@:+
M,<4N(&!04Z]]-38WX4=,Y@T[JFE3<SADFF0)ZIS^2!U'C:U9D]Z^R-6;?F]H
M)<`R],_9ZX4TV<=2C"&[Y=2V(5.4LK(C=$JBMF70LP([?`0H>.O#JMESINT2
M'X`01\4`[0X#J'-T]A-7[3N)K:]::RR.":7V@2CJ!F)`_)!(;/>(W1N[Y7;J
M+-07QN0++I&92N81S,N!'5"C_,6G:'9^;4)YAQY0068>S,9HOKJL.A%GKW8?
MP-E3IUY<?YQN9I9)<?-T;JQ]=BG(9ZSODIBH1<(R1.8`6-=:I4V"@`',4BO-
MV%XR)M5<KM0:S819B55#IRK3_8)Q)Z)=,:1N!2TM3IQUQ^6=H%2>V7*(POQ5
MQ;)G4+R+BW)S%Y0$Y53)`;E,;M'E-P`!T?[YI<B6I'WU2?(%RZ>V!$]IU009
MM9S(](!^<8Q)1_+K6SMIANGI:,M@-^24N6X9J45S1(R";=&XDL@-5_#>Q<BB
MFJJJG%QISJ$C^;@9$1$.\``7==Z]KU<ZQ>"H*;/J#'*4\B#P/7*"MV\IJ!BP
M-N4V7OW?:E(GEYO+"^^HVB18PJ]WTZ:OV8\W/9\T1P?S-'WETM_#6T_[/8Z-
M;8'[FG^(7^E`S;N_>3_#1^BJ'#7RL'W?%T?QFN[^M+ZAS?[[\)_AQZ8DO:;[
MLG]K\PA0'K??=A[H_P!R5/V@ZTO;#[_V_P#;I^>-CU[]U:SZ!B/^Z-WWDVU'
M]["_L4=&?NX/_HMR_9#YH''07WFI_P"('_7$K$'ZT?P_ZM<\>8\OI,&`/8\L
M9M.AD,E-^5INK^ZD^0["8*&(O>64(RWFQB?7!:36(B`E'M`0_-KJ[M!>&['L
M#17BL(31T5O6XD<E*`)$_-'$??.S5&H/$Q=K"R,U1679MN8XA*BD2'D./9#N
M;!NWG%F#L>6[9EBV="Q",="Q[=Z\*S1-(2;H&Y#NG$D]$A5WBRCDYAJ<1IP#
MNUS%U-K&^:JOCUWN54XZMQY2TC,0$()P`'"0CKYHW0>G=&:>9L=EI&FN[80E
M2BD$K7E$R2<2281IZT6T6Q$,7L=R=BP+"U[FM>328WLK#MDFC2<A)!8$VKMV
MU1*1,9-O+K)T7&I^0*:*OPB[G71C5#VA[FKWNVUJ?4S*)R'@1CR(Y0&7C4V>
MLSNEV=P[.V*:\T2P%I2`D+!,RK#F.,;9CG,\GFCHW93?3[DSJ;M"P[BLMZJ<
MH`8S6!E(]G%&.;F$3J':)!4W?2NL3?\`2;>C/%7;[4A`13/W!#R`.6<*)`Z)
M1F+#KG[=>#6Z7%;BA74EN6PX3Q]0H$_+&A]&F^8_&>T#<-D26`1C;*G;AN-Z
M0H\IC-HIHJZ5`!#B'!/6P>+JSNZDW0LMII#]>^TRV.TJE+Y8P'@PO*--[3:A
MOE09L404X?\`E:4KYH)OTZ\#I[Y]VF3,S9E(>X+5MR6<W;,LW2@BVGIN4DEV
M\%'+$$#@9BQ;M43'2XE.%0$*#J0M^=6L[-[86O26F5K8JWT!ES+^4$@J5RXY
MI3B(?#?HM>^N\-TUUJ8*?H*=9>0%>R0I9"4XGB)<(=??!EJ(PA+<+;D*$"5L
M#)*!!BW]S@R!/P@:`Q\,6X(>'P$O+2G=KG6Y<*[WL5:JI\5:C/,5'CQ_XQCJ
MZ;)9E49H11LFB2F64H3+T'E#3OJ2X(4V1;M+#S3A@XVM!72Y0O.$9QQ@21@9
M>)?H(S\>@1,"`G'27FE#$3"@$+0`"FND>P&K6MYMM*_;K62^]JJ=M24+5Q(*
M3EQZ00,8Y2>([2E1L/O!;=Q-(9&K75.)<0A/_D!]<$8"1F90Y'^TA$_9!^U!
MX0>0_P#4_P`?>6_Y_N[G\#DK];S7"F@,^PER_F#_`"\D>_\`?_=Y\_;E.?T<
M8Z,?S$H?Y5?S.D,OPWWF7+-EX2^E\D&F5*0"`(CPI2O-R@`>DPCPIK0PM:`E
M+>.8Q*10A:R\N4@(CY/F+NJ!&;G<M,]J&&9LK[#^$)N0-?4VU2$C.\<B)H"S
M7:(K<XA(P4,D8O(-`*5TF8>T-&#L=MTY:J8ZM=]2Z5`RA)PDUQF>TP.6YNKF
M:]X62D/U#:R9CCFX8&$R[?Z6.X:Y.G5</4):Q2Y;1AKX38L[1$AC3,EC-JR4
M:S-_$;@7Q0"/NGD9IH4J=`PJ@:@4U)#FYMAI]7_9!]P$+:(*N07,>K/IC56M
M&73X!\9;3ZX5A]&7'T09'H/=1HVQ[=7&6GD.YE8S;QG%XQM>]4G`'7C("Y5J
M-;=O!8I3`9HW8F,9%80*;F\<!'LUKF\^WR-3Z<^)4(S55(,R)<5#F!Z9QE=M
M-0&P7GW*JD*>IP6>$L<"<<3,RPQE$EVS>M7S5L\9JD<-'B"+ILX2'F26;N$B
MK(K)G`1`Q%$S@(#H%AWWO!IZD26.'D@I&W$/([QHYDRC,(A2@!0`-^/UZ]<Q
M4DSY&4>:U%223QF!$<-\S1]Y=+?PUM/^SV.C8V!^YI_B%_I0,V[OWD_PT?HJ
MAPU\K!]WQ='\9KN_K2^H<W^^_"?X<>F)+VF^[)_:_,(4!ZWWW8>Z/]R5/V@Z
MTO;#[_V_]NGYXV/7OW5K/H&(_P`Z.(E#J2;3A$W'XN$`+W_J4..C2W<=>.@J
MYA"FPG(,#QY0.6@E$:C9^K"AWXQ\JO1\\2L(\%*\>`FI00&O$>T*\*:YV!W)
MF29>B"]*SE(/##AQB\#\>PWY/Y=-+PD<!YX\Q*?XT,^,VNV#'K.13F4,0D>C
MN/LE1TJ?BFF1)\!A,81X`!1[==-=*4]0[X2BRR)U:;.3(=BHX\:J?9HO&>:A
MXRIVM1I<)^DML^D0\!**:A2F`0,40`Z9@[!*<`,00$.%!*(:YEN!:62D?WAP
M^7G'84K8>4%JQ(D1Y0(2YZP\[$QFQ/*,:_<@W=W$O`QL0B8*"Z=-YV.?+I%J
M-0$K5L<]?0&I[\,=OJ[KN]:RVGZMHE2NP`X]D##XP*VGHMF*]-0L"H?=;2V.
MGUDDCR`3A.S:5!O8KHV[EI1VB9%K/-KQ<1QCCQ5192[1N=0I1[`$YPIZ=3WN
MM64-7XO+4BC5F;144P5VY%0.FT-%6T?@PU"[4((+C52I$^8*TXQK?3HAI&X^
MFIO7@X8JAY63B;Z:L")!_.J+'B5^4A`#C500I^'5SX@:UFW>(73U7584;3C*
MR>I2T^B46'AJMS]R\-VL*.C&:M?I76P.<ULD>B-XZ"-PPS0N=+,56(6XB&AI
M7RO#Q%6/FUF2ABF$0$QDG29N8*<`"NL3XVJ-\JLUPI@3;LQ,^4R$GT1DO`'>
M&&3?;,^0+BD(6$GB9$@RZ9$"'(O,0I!$0$.(5IQ,(C0.&@9<:<<(*"`9S\D=
M)BZEA.<B8D#ATF&V_7QN*(5=X,M9-0AYT65P20-RT%0C3S[1L4AQK4HK*&`0
M"G'1V>"YNH;>O%T0DII^[",QX3D21\D<UO\`]!+FPXNQV5M055**EJ2.(!P'
MG)@[/PU,_P#QS]P^2-[W^S3XODJ#XO+Y3Q^6E*\_A<::B3XS;O\`<Q\1S?Z#
MXU/-RXRGYXG3X+5_[/\`X5W9]]^SOL\^'X(X-U[NI9&;&]KBU@V7<[-CG_.Z
M3NUK.9MWK="5MVVE$13N2[#\ROC,%&C-P'E#F*`**%,`=FH]VGT*YK*^!#^5
M%K9&968R)ZL>,3]K;4+UFL9]T255B\.!,@>SM$NV&'_3TV?7EU#-V5DX-MUT
MG(M9F9+=65[E<.^<L=9;>0"1NIX\<%.*@R$VW!RB@:H5<'"E>S19ZOU50:+L
M+CR5HSMM]TVA)F292!,#UIG3=7J*](2ZAQ`*LRB<.!F9'I&!Z8E2H?!.,[>P
MFQV^1MLQJ6+&=AIXW"W#LVIF2MNDA0A#>80\($572R!?$.IR\QEO;^MQT`:;
MD_4W==Y6M?OA>[P&9XS\\H+=NWT[5O%M0!W"6\@'5*7GYQ%X]5#8I<73TW8W
MEBZ30*UQY/NU+OPU-^()6S^U'CCQV;!NX.<H#(6Z(II+``B)#B&C_P!O=:46
MK-*)-6\VFO;3D*3@)C`S!X]1@3M66*KLE]4.Z66"<P*>@XC'KGCT0[X^7-ZH
M\3N>PPSV@97NQ)_G["<*J2VWCY^@N^O[&;`"$8O$%A.9:1EH!/F!Z;VN5,Z=
M:!30M;P:+8T]?OBE"4&@<,_5/!1X^0Q-FV^J7KE3"WUB5BK2F8F"!(<L>C&'
M/`%.-`$2T*/KK3UB(ZB%80I)R\3C$F/36L9)9.<1OOS-;MHCU,)9-=R@BH.-
M+5,4BJR:9A*#!@',!3&*:G'MT9NPKC5/I%1J7VT-]^H@'`XGM@:]V*>H7?R\
M&UJ;[M(F`>("H<-_*MKIK]/6ZCHJI*E#--WE`Z9RJ$$0>+A2I1$*AJ(-^WF'
M=;A;"PMON!B(DG:MIQO3I;4E25YYR5V0H'UP%`2Z86Z8ZQB)IDLDXF.<P$*7
MVQ$1,8P@`!K3=M"E.N[:YF"4>\)F3T1GM=$_91\*25+4F1`ZXC!<39AN["UZ
MVKE'&-XFM*_+24*]MVY8QRS!_%NC)E`R[;QP72`X@`?6*(<-'K=FK->:1ZVW
M$LNTKF!,\988<8%*FJ+G:ZX5-`AQ#B%3Q!/K`G'E"C@]<WJ=B83?;/R'4W$:
M.[;#\@1```?1PUH*=L-M0)>[L$=HC85ZWUPMPN!YX*/0DR@#US>IX`"(;T,B
M5IP_IEN=O=_VC2.V&VI!`IF)RZ1"&M]<@@]^_P`?R3!S]N60\Y[JYJP[]D+M
M<Y"W`7I(IS2<[)OF24O-W%'G(JU$%&Z:*7G#&-[`%)Q'NT1UD>T;H[:A-!?'
M`S95TIIW$@YE)0<)B7/'C'/;<&WZNU!OS4U5D86Y?#4IJ!@0%+1C+^B'1N(>
MMMB.W[4C[0W%VC=]CY0M9!.!N9LRC%9`CF5B_P"A+KBP22\['\Y40,(*\35J
M'`0T$^H?"WJBXU*KMH*HI:O3U2HK965@$!6(2H3Y0;^EO&=I.@MXM6XM%6T&
MH:63;H#94E10`,PD,)RX<83WW8;H,I]4[)=G8/V_V/,CCZ#FP721%5-859!V
M8S=:X[I?MB>6AHYM%JG%--QRCST*`B8>,[;8:!T[X=;+4ZSU]7,'5):(2AM0
M4D)RSR`<U%7,=D#_`+N[I:C\46HJ+1N@**H&G&Z@$K6DHX^KF5.6&7IA:K/.
M&HC;YTP<H8JC?!$ELX=<)RBZ=`1=3*KJ+/+/"&J`<KAYS&"O&@Z$K2NJW=9;
M^6[4Y)#E7<@4!1P"!,)!Z))@SM<:(:V_\,EVTK0#,JGM2@KGF6HHSREQQ&$%
M/Z$247*[?,M,E/`?L75]2#1T@;D60426(*2J*P!S%$I@-0:]VI6\9]4A>X-"
MY1*S/,4;1FDXYDF<1%X%*(G;RZ,5S93WU0`L*$DD9)8`]I@A.4\:9YZ5F[*1
MS19-NOYW#\U.2*K)XR`ZL-(6M+*BY<P=Q+D`S>)>M5%E?`,L8I0$0&@ZEVT7
MO1OB1VVI=*W:J12ZNIFQZJO5]=*<H5CB4F0X<X@2]:1U[X6-VW=866G76:->
M<40L>M-IPS*5`<%)GAA*%,#]=;:N2T$Y<T!>871Y0J@VJ#,`;^;\,!,W"XA1
M]UBW!3AXGU>74`_[0]UA<C39Z+W+O)!T/)RA$Y3E/C+&4$\?')M/\*-0VU7*
MN:4B;'<JF5D<C*4@><)DV)BS/'5BW3(YDNBWI&VL.1LS&!(2L@"Q(>/M.'4!
M5O!VNL)2(3$D^!),7!VYC$Y@&H:(2_Z@T=X:MME:4M=2W5ZOJ`2L(Q]=0*9S
M&(2)P,MCT5KWQ2;NC6E^IW*32*%)""J8`;000`#S,L8=B_`]O?!?P#[L;_"W
MP_\`#?NKPR^7]U>4\KY;P^SD\/NUSH^(U/Q#XM,^]][WD^>;-FCJQ\'HO@WP
M'(GW#N.YERRY<O9PCP+MPSBB_P!\UDK]Q;CN^)!F@+9K(7A9ELW,_:MQ`0\!
ML\G(Q^X01H(U*0P%]6FTM?<Z`$4-2ZU/CE4I,_S2(NG[=0U/]^A*_I`'T@Q2
MT\,8GL.2<RMBXLQW8\@Z;$:.9"T+*M>VI!TV34%4C99["1C%RJW(H/,!#&$M
M>[2K*^X5K815ONN@&<EJ4K](F&T]!1TKOO%.TA#TI3"4C#R`1TXI3`%!XAZZ
M5IZ!U9J2%24!)47RR#(CC..?7KB;&>15F#J_<<6%?#B*342C5KPL^W+G69)+
M&*=9%FK.1KY1HFJ8H"8$Q*!A#CJ]IZZMHD%-&\ZV"<<JE)G^:1%D_14M4^%U
M+:%I`YI!](,>=:V#<,V/-)W%9.(,8V=/H(+M6\[:]A6G;TNBU=E*5VV2DH>)
M9ODV[HA`!1,%`(H``!@&FF/7&YUP+5>\ZXSRS+4K](F&M6ZBI5=[2-MH>Z0E
M(]`$=0*4X_6*``(C6@_EU;(GE(.'1V1>Y&Y3_&^>.873A'#]\ROOV]L2XRO"
M:%(&YI>Z+#M2X94Z!!`$T32,Q$O'HI%`H4+S\H4U<IN-TI&.ZH7W4#H"U)'F
M!`BS>H*2K,ZMIM?:E)](,;+:EAV=848:'L.S[6LJ)47.Y4B;4@(BVXX[E01%
M1R=E"M&34RYQ&IC"7F-WCKR=J*JJJ>_K'%N'+*:B5'SDDRBZIV*:F1W;*$H1
MU``>881ZMPVY!77$.X*Y82'N*%D"`D_AY^,93$4\2[R.HZ00<LW)?T5"&+JB
M'7F7$NL*4EQ)P()!\XD1"<;:>3W;R0IOH(F/ECD9=L6W$H<OV><'#3A[.*+`
M`*4H%`^'^&L@J]7P^S65`_Q'/UHL%6NU@^K2LD?01^"*_9CVX?Y>,'_X46!_
M=[3?C-]_?:C_`#'/UHI\,MO[HQ^8C]6*?9CVX?Y>,'_X46!_=[2^,W[]]J/\
MQS]:%\,MO[HQ^8C]6-BA<)XEMATQ>6QB['=N.HT_/'N8.RK9BEF!^Y1B=C&(
M&:*%[C$$HAKU?OEZK*55)6U=0ZTKB%.+(\Q,8ZGTKIRDN*;NQ04R;D,.\#:`
MK'CZP$XT?(>TW;QE=\I*Y!Q%9EQ2JJAE%9%6);,GZYS``&5=O(XK5=TH8`XB
MH8XZS5DW$USIAD4MCN-2U2@8("_5'6`9R\DHP=]VJV[U'5*K;S::.HJUF:E*
M0`3VRE/RX]<=`L'$6.L6L0CL=V-:UGM@1(V-[BAHY@Y60)02D=OD&Y'CR@A7
M^<.;6%NVH+_J&H557ZK>J5JG@M1(GV3D/)&>L>D],Z;9[BP4%-1I`XMH2#YP
M)R\L;I*P[&;8.8J7C6,I&O41;NX^0:MWC)RD(@(I.6CDBC==$1+42F*(5`.&
ML6TX_2+0[1*+;[9FE:3)23U$8CR1EZFD8N%&JDN#:7:=8DM"@"E0ZP<#'D6Q
M8]K6:V79VK;%NVPT=*F7<M;=AXZ&;N%C\3*K(QS9LFHJ(]IC`(ZNZRXW&XO"
MHN#[KSR1(%:E*,NU1)BRMU@LMGIS2VBF:IF'#-:6TI2)]@`CT9VW(>Y(Y>*G
MH:*G(QP6B\9,,6TDQ<4#AXC5XFLW,/K$NK:EJJ^BJ/>J)Y3-1^4@E)EVB4>]
M=:K;=:<4-S9;?HOR5I"AVX@P6H-C6U'WN,\."[$"346\RHH6-+Y?Q:\W!@8?
M(`3F'ZH)@7U4UO+>Z6XS=+[F+Q5]QT9SZ>,1PK8S:85AKF[)1IJ2J>8(D9]/
M1!EH*VX2V(MM"VY#Q<#$M0Y6\9#L6D8P0`:5\)HR210(8:<1`O'6D5=157&L
M-=<'G'J@\2M142>TDQ)5);J"W4J:"W,ML4:1[*`$CS"4>_ZM>47DL)<HL#GK
MQ[/P:45B_2A10U:>SVU]7Y]*%`"M./;I0HKI0H&E"@:4*!I0H&E"@:4*!I0H
>&E"@:4*!I0H&E"@:4*!I0H&E"@:4*!I0H&E"C__9
`
end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
-----END PRIVACY-ENHANCED MESSAGE-----
